Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
76°
Partly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,199.12
+11.46 (+0.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Where Will Regeneron Pharmaceuticals Be in 1 Year?
December 22, 2023
Can the stock continue its market-beating ways?
Via
The Motley Fool
7 Undervalued Nasdaq-100 Stocks for Bargain Hunters
December 21, 2023
Though tech innovators blossomed this year, you can still find undervalued deals.
Via
InvestorPlace
$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
December 21, 2023
Via
Benzinga
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
December 18, 2023
Via
Benzinga
Price Over Earnings Overview: Regeneron Pharmaceuticals
December 18, 2023
Via
Benzinga
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
December 17, 2023
You can pick these players up for a great price right now.
Via
The Motley Fool
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
December 11, 2023
Via
Benzinga
11 Analysts Have This to Say About Regeneron Pharmaceuticals
November 28, 2023
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
November 17, 2023
Via
Benzinga
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Stocks to Buy Before 2024 That Can Set You Up For Life
December 14, 2023
These stocks are still relatively cheap, but don't expect them to stay that way for long.
Via
The Motley Fool
Reasonable growth and debt and a high ROIC for REGENERON PHARMACEUTICALS (NASDAQ:REGN).
December 14, 2023
Exploring REGENERON PHARMACEUTICALS (NASDAQ:REGN)'s quality characteristics.
Via
Chartmill
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
How Is The Market Feeling About Regeneron Pharmaceuticals?
November 16, 2023
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
November 09, 2023
Via
Benzinga
2 Soaring Stocks to Buy and Hold
November 09, 2023
Both of these companies crushed earnings season.
Via
The Motley Fool
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
December 08, 2023
Regeneron has been an excellent investment in recent years. Can that trend continue?
Via
The Motley Fool
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
December 06, 2023
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places
December 02, 2023
The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
December 01, 2023
Via
Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
November 27, 2023
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
Via
Talk Markets
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
November 27, 2023
Regeneron and Sanofi are partnered on Dupixent, a treatment for conditions tied to type 2 inflammation.
Via
Investor's Business Daily
Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
November 27, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
November 16, 2023
Via
Benzinga
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
3 Biotech Stocks That Are Betting on the Future of Gene Editing
November 09, 2023
These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.
Via
InvestorPlace
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
November 06, 2023
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases.
Via
Investor's Business Daily
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
November 06, 2023
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.